公开(公告)号：US20230357347A1

公开(公告)日：2023-11-09

申请号：US18087063

申请日：2022-12-22

Applicant: Carmot Therapeutics, Inc.

Inventor： Johan Enquist ,  Shyam Krishnan ,  Suman Atwal ,  Daniel Erlanson ,  Raymond V. Fucini ,  Stig Hansen ,  Andrew Sawayama ,  Steven Sethofer

IPC: C07K14/605 ,  A61K47/54

CPC classification number: C07K14/605 ,  A61K47/545 ,  A61K38/00

Abstract: This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt and/or hydrate and/or prodrug of the compound) that modulate (e.g., agonize or partially agonize or antagonize) glucagon-like peptide-1 receptor (“GLP-1R”) and/or the gastric inhibitory polypeptide receptor (“GIPR”). The chemical entities are useful, e.g., for treating a subject (e.g., a human) having a disease, disorder, or condition in which modulation (e.g., agonism, partial agonism or antagonism) of GLP-1R and/or GIPR activities is beneficial for the treatment or prevention of the underlying pathology and/or symptoms and/or progression of the disease, disorder, or condition. In some embodiments, the modulation results in an enhancement of (e.g., an increase in) existing levels (e.g., normal or below normal levels) of GLP-1R and/or GIPR activity (e.g., signaling). In some embodiments, the chemical entities described herein further modulate (e.g., attenuate, uncouple) β-arrestin signaling relative to what is observed with the native ligand. This disclosure also features compositions as well as other methods of using and making the said chemical entities.

公开(公告)号：US20240383960A1

公开(公告)日：2024-11-21

申请号：US18777223

申请日：2024-07-18

Applicant: Carmot Therapeutics Inc.

Inventor： Daniel Erlanson ,  Raymond V. Fucini ,  Stig Hansen ,  Jeff Iwig ,  Shyam Krishnan ,  Enrique Moya ,  Steven Sethofer

IPC: C07K14/605 ,  A61K38/00

Abstract: This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt) that modulate (e.g., agonize or partially agonize or antagonize) glucagon-like peptide-1 receptor (“GLP-1R”) and/or the gastric inhibitory polypeptide receptor (“GIPR”). The chemical entities are useful, e.g., for treating a disease, disorder, or condition in which modulation (e.g., agonism, partial agonism or antagonism) of GLP-1R and/or GIPR activities is beneficial for the treatment or prevention of the underlying pathology and/or symptoms and/or progression of the disease, disorder, or condition. In some embodiments, modulation results in enhancement of (e.g., increases) existing levels (e.g., normal or below normal levels) of GLP-1R and/or GIPR activity (e.g., signaling). In some embodiments, the chemical entities described herein further modulate (e.g., attenuate, uncouple) □-arrestin signaling relative to what is observed with the native ligand. This disclosure also features compositions as well as other methods of using and making the said chemical entities.

公开(公告)号：US20230151074A1

公开(公告)日：2023-05-18

申请号：US17744540

申请日：2022-05-13

Applicant: Carmot Therapeutics, Inc.

Inventor： Daniel Erlanson ,  Raymond V. Fucini ,  Stig Hansen ,  Jeff Iwig ,  Shyam Krishnan ,  Enrique Moya ,  Steven Sethofer

IPC: C07K14/605

CPC classification number: C07K14/605 ,  A61K38/00

Abstract: This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt) that modulate (e.g., agonize or partially agonize or antagonize) glucagon-like peptide-1 receptor (“GLP-1R”) and/or the gastric inhibitory polypeptide receptor (“GIPR”). The chemical entities are useful, e.g., for treating a disease, disorder, or condition in which modulation (e.g., agonism, partial agonism or antagonism) of GLP-1R and/or GIPR activities is beneficial for the treatment or prevention of the underlying pathology and/or symptoms and/or progression of the disease, disorder, or condition. In some embodiments, modulation results in enhancement of (e.g., increases) existing levels (e.g., normal or below normal levels) of GLP-1R and/or GIPR activity (e.g., signaling). In some embodiments, the chemical entities described herein further modulate (e.g., attenuate, uncouple) β-arrestin signaling relative to what is observed with the native ligand. This disclosure also features compositions as well as other methods of using and making the said chemical entities.

公开(公告)号：US11535660B1

公开(公告)日：2022-12-27

申请号：US17040653

申请日：2019-03-22

Applicant: Carmot Therapeutics, Inc.

Inventor： Johan Enquist ,  Shyam Krishnan ,  Suman Atwal ,  Daniel Erlanson ,  Raymond V. Fucini ,  Stig Hansen ,  Andrew Sawayama ,  Steven Sethofer

IPC: C07K14/605 ,  A61K38/00 ,  A61K47/54

Abstract: This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt and/or hydrate and/or prodrug of the compound) that modulate (e.g., agonize or partially agonize or antagonize) glucagon?like peptide?1 receptor (“GLP?1R”) and/or the gastric inhibitory polypeptide receptor (“GIPR”). The chemical entities are useful, e.g., for treating a subject (e.g., a human) having a disease, disorder, or condition in which modulation (e.g., agonism, partial agonism or antagonism) of GLP?1R and/or GIPR activities is beneficial for the treatment or prevention of the underlying pathology and/or symptoms and/or progression of the disease, disorder, or condition. In some embodiments, the modulation results in an enhancement of (e.g., an increase in) existing levels (e.g., normal or below normal levels) of GLP?1R and/or GIPR activity (e.g., signaling). In some embodiments, the chemical entities described herein further modulate (e.g., attenuate, uncouple)-arrestin signaling relative to what is observed with the native ligand. This disclosure also features compositions as well as other methods of using and making the said chemical entities.